AC
CRL icon

Avestar Capital’s Charles River Laboratories CRL Stock Holding History

Avestar Capital’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-1,287
Closed -$349K – 470
2024
Q1 		$349K Sell
1,287
-44
-3% -$10.5K 0.04% 307
2023
Q4 		$315K Sell
1,331
-119
-8% -$23.4K 0.04% 286
2023
Q3 		$284K Buy
1,450
+17
+1% +$3.49K 0.04% 266
2023
Q2 		$301K Buy
+1,433
New +$285K 0.05% 233

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Meritage Group San Francisco, California $2.6B AUM 15.71% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.4B AUM 49.36% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

Avestar Capital's CRL Position: Q2 2024 in Review

Avestar Capital sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 1,287 shares — an estimated $349K sold.

Avestar Capital first reported a position in CRL in Q2 2023 and held it in 4 quarters. The position peaked at $349K in Q1 2024. 665 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

  • Avestar Capital reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
  • Avestar Capital sold 1,287 Charles River Laboratories shares in Q2 2024, an estimated $349K.
  • Avestar Capital first reported a position in Charles River Laboratories in Q2 2023 and held it in 4 quarters.
  • Avestar Capital's Charles River Laboratories position peaked at $349K in Q1 2024.
  • 665 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Avestar Capital's 13F filing for Q2 2024, filed 8 Aug 2024.